The biopharmaceutical industry is slowly absorbing the idea of collaborative patent licensing models. Recently, two patent pools for developing countries have been launched: the Pool for Open Innovation against Neglected Tropical Diseases initiated by GlaxoSmithKline (GSK), which is referred to as the BIO Ventures for Global Health (BVGH) pool, and the Medicines Patent Pool (MPP) initiated by UNITAID. Various organizations have recommended using pools or clearinghouses beyond the humanitarian dimension where many patents are owned by many different actors. As a first attempt, MPEG LA, which administers patent pools in various technology fields, is now setting up a clearinghouse for patents related to molecular diagnostics. These examples as...
Companies share their intellectual property with potential competitors in many different ways, inclu...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
The present chapter aims at re-visiting our former insights on the anti-commons effect in life scien...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
Abstract: Developing and delivering appropriate, affordable, well-adapted medicines for HIV/AIDS rem...
As countries are still in the thick of fighting the COVID-19 health crisis and scientists and pharma...
A patent pool is an arrangement under which patent holders in a common technology commit their pat...
May 2006Prepared for Workshop "Gene patents and clearing models", June 8-10 2006, Centre for Intelle...
The presentation expands on the concept of “thickets” in Intellectual Property Rights such as when a...
Companies share their intellectual property with potential competitors in many different ways, inclu...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
The present chapter aims at re-visiting our former insights on the anti-commons effect in life scien...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
Abstract: Developing and delivering appropriate, affordable, well-adapted medicines for HIV/AIDS rem...
As countries are still in the thick of fighting the COVID-19 health crisis and scientists and pharma...
A patent pool is an arrangement under which patent holders in a common technology commit their pat...
May 2006Prepared for Workshop "Gene patents and clearing models", June 8-10 2006, Centre for Intelle...
The presentation expands on the concept of “thickets” in Intellectual Property Rights such as when a...
Companies share their intellectual property with potential competitors in many different ways, inclu...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...
In 2021, pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medication...